MEDIA

MEDIA - NEWS AND UPCOMING EVENTS

Media Contact:

Julie A. Fotheringham - Partner, Hageman Communications
Julie.fotheringham@hageman.ca  416-951-7988

NEWS ARCHIVES

NEWS

Interface Biologics Announces New V.P., Business Development
Interface Biologics Inc. (“IBI”), a privately held, commercial stage developer of innovative material science technologies for Medtech and Pharmaceutical applications, is pleased to announce the addition of Kelley Dealhoy, to the IBI management team, as Vice President of Business Development.
Interface Biologics Completes Pre-IND Meeting with U.S. FDA on Epidel® Technology for treatment of Posterior Inflammatory Eye Diseases
Interface Biologics Inc. (“IBI”), a privately held, commercial stage developer of innovative material science technologies for Medtech and Pharmaceutical applications, is pleased to announce a positive pre-IND (Investigational New Drug) meeting with the U.S. Food and Drug Administration (FDA) for its novel dexamethasone intravitreal implant for the treatment of posterior inflammatory eye diseases.
Paul Santerre named Baxter Chair of Health Technology and Commercialization
U of T professor Paul Santerre (Dentistry, IBBME) has been named the Baxter Chair of Health Technology and Commercialization. Created through a $2.5-million investment from the Baxter Corporation to the University Health Network (UHN), the chair will enable Santerre to drive commercialization and entrepreneurship initiatives at both UHN and U of T.
Powered by Innovasium